Compare
Heron Therapeutics, Inc. vs Liquidia Corp vs Elite Pharmaceuticals Inc vs Phathom Pharmaceuticals, Inc.
| Latest fiscal year | Heron Therapeutics, Inc. HRTX | Liquidia Corp LQDA | Elite Pharmaceuticals Inc ELTP | Phathom Pharmaceuticals, Inc. PHAT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | $154.90M | $158.32M | $148.87M | $175.11M |
| Revenue growth (YoY) | +7.4% | n/m | +77.1% | +216.9% |
| Gross margin | 73.3% | n/a | 50.4% | 87.1% |
| Operating margin | -1.6% | -32.5% | 33.0% | -91.4% |
| Net margin | -13.0% | -43.5% | 30.1% | -126.3% |
| Net income | -$20.20M | -$68.92M | $44.87M | -$221.25M |
| EPS (Diluted) | -$0.12 | -$0.80 | $0.03 | -$3.03 |
| Operating cash flow | -$27.59M | -$35.69M | $23.75M | -$166.78M |
| Free cash flow | -$27.91M | -$40.02M | $22.82M | -$167.00M |
| Cash & equivalents | $28.65M | $190.68M | n/a | $129.97M |
| Total assets | $255.88M | $327.93M | $138.29M | $259.15M |
| Total liabilities | $241.54M | $283.19M | $39.41M | $697.32M |
| Shareholders' equity | $14.33M | $44.75M | $98.88M | -$438.17M |
| Return on year-end equity | -140.9% | -154.0% | 45.4% | n/a |
| Shares outstanding | 188.31M | 87.20M | 1.08B | 71.42M |
Revenue, most recent five fiscal years
| Fiscal year | Heron Therapeutics, Inc. | Liquidia Corp | Elite Pharmaceuticals Inc | Phathom Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $154.90M Ended 2025-12-31 | $158.32M Ended 2025-12-31 | $148.87M Ended 2026-03-31 | $175.11M Ended 2025-12-31 |
| 1 year earlier | $144.28M Ended 2024-12-31 | $14.00M Ended 2024-12-31 | $84.04M Ended 2025-03-31 | $55.25M Ended 2024-12-31 |
| 2 years earlier | $127.04M Ended 2023-12-31 | $17.49M Ended 2023-12-31 | $56.63M Ended 2024-03-31 | $682.0K Ended 2023-12-31 |
| 3 years earlier | $107.67M Ended 2022-12-31 | $15.94M Ended 2022-12-31 | $34.16M Ended 2023-03-31 | $0 Ended 2022-12-31 |
| 4 years earlier | $86.35M Ended 2021-12-31 | $12.85M Ended 2021-12-31 | $32.26M Ended 2022-03-31 | n/a |